TABLE OF CONTENTS
1 INTRODUCTION 208
1.1 OBJECTIVES OF THE STUDY 208
1.2 MARKET DEFINITION 208
1.3 OVERVIEW OF THE NORTH AMERICA FAT REDUCTION MARKET 208
1.4 CURRENCY AND PRICING 210
1.5 LIMITATIONS 210
1.6 MARKETS COVERED 211
2 MARKET SEGMENTATION 216
2.1 MARKETS COVERED 216
2.2 GEOGRAPHICAL SCOPE 217
2.3 YEARS CONSIDERED FOR THE STUDY 218
2.4 DBMR TRIPOD DATA VALIDATION MODEL 219
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 222
2.6 MULTIVARIATE MODELLING 223
2.7 TYPE LIFELINE CURVE 223
2.8 DBMR MARKET POSITION GRID 224
2.9 VENDOR SHARE ANALYSIS 225
2.10 MARKET APPLICATION COVERAGE GRID 226
2.11 SECONDARY SOURCES 227
2.12 ASSUMPTIONS 227
3 EXECUTIVE SUMMARY 228
4 PREMIUM INSIGHT 232
4.1 PESTEL ANALYSIS 234
4.2 PORTERS FIVE FORCES 235
4.3 MARKET ANALYSIS 236
4.4 NORTH AMERICA (PRICING AND PROCEDURE ANALYSIS) 237
4.4.1 U.S. 237
4.4.2 CANADA 238
4.4.3 MEXICO 239
4.4.4 COSTA RICA 240
4.4.5 DOMINICIAN REPUBLIC 241
4.4.6 PANAMA 242
4.4.7 EL SALVADOR 243
4.4.8 GAUTEMALA 244
4.4.9 HONDURAS 245
4.4.10 NICARAGUA 246
4.5 BRAND ANALYSIS 247
4.5.1 KYBELLA 247
4.5.2 AQUALYX 248
4.6 PRICING ANALYSIS (USD) 249
4.6.1 NORTH AMERICA 249
4.6.1.1 U.S. 249
4.6.1.2 CANADA 249
4.6.1.3 MEXICO 249
4.6.1.4 COSTA RICA 250
4.6.1.5 DOMINICIAN REPUBLIC 250
4.6.1.6 PANAMA 250
4.6.1.7 EL SALVADOR 251
4.6.1.8 GAUTEMALA 251
4.6.1.9 HONDURAS 251
4.6.1.10 NICARAGUA 252
4.7 PATENT ANALYSIS OF THE NORTH AMERICA FAT REDUCTION MARKET 253
4.7.1 U.S. 253
4.7.1.1 METHODS FOR THE PURIFICATION OF DEOXYCHOLIC ACID 253
4.7.1.2 COMPOSITIONS COMPRISING DEOXYCHOLIC ACID AND SALTS THEREOF SUITABLE FOR USE IN TREATING EAT DEPOSITS 254
4.7.1.3 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF 255
4.7.1.4 SYNTHETIC BILE ACID COMPOSITIONS AND METHODS 255
4.7.2 CANADA 256
4.7.2.1 SYNTHETIC BILE ACID COMPOSITIONS AND METHODS 256
4.7.2.2 BELKYRA 256
4.7.2.3 BELKYRA 257
4.7.2.4 BELKYRA 257
4.7.3 MEXICO 258
4.7.3.1 FORMULATIONS OF DEOXYCHOLIC ACID AND SALTS THEREOF. 258
4.7.3.2 TREATMENTS OF ACCUMULATED FAT WITH DEOXYCHOLIC ACID AND SALTS THEREOF. 258
4.8 PRICING ANALYSIS (USD) 259
4.8.1 KYBELLA 259
4.8.2 COOLSCULPTING 261
4.8.3 COOLSCULPTING ELITE 263
4.8.4 COOLTONE 265
5 INDUSTRY INSIGHTS: 268
5.1 DEMOGRAPHIC TRENDS: 269
5.2 CONCLUSION: 270
6 NORTH AMERICA FAT REDUCTION MARKET, REGULATIONS 271
6.1 U.S. 271
6.1.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE: 271
6.1.2 POST-MARKETING SURVEILLANCE: 273
6.1.3 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES: 273
6.2 CANADA 274
6.2.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 274
6.2.2 LICENSING AND REGISTRATION 275
6.2.3 POST EXPIRY OF PATENT REGIME 275
6.2.4 POST-MARKETING SURVEILLANCE 275
6.3 MEXICO 276
6.3.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 276
6.3.2 REGULATORY APPROVAL AGENCIES 276
6.3.3 LICENSING AND REGISTRATION 277
6.3.4 POST-MARKETING SURVEILLANCE 277
6.4 DOMINICAN REPUBLIC 277
6.4.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 277
6.4.2 RENEWAL OF REGISTRATION IS REQUIRED IF THERE IS A CHANGE IN PRODUCT FORMULATION OR A CHANGE IN THE SITE OF MANUFACTURE. 278
6.4.3 TIMELINE 279
6.5 GUATEMALA 279
6.5.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 279
6.5.2 REGULATORY APPROVAL AGENCIES 279
6.5.3 LICENSING AND REGISTRATION 280
6.5.4 POST-MARKETING SURVEILLANCE 280
6.5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 280
6.6 HONDURAS 280
6.6.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 280
6.6.2 REGULATORY APPROVAL AGENCIES 280
6.7 NICARAGUA 281
6.7.1 REGULATORY APPROVAL PROCESS, PATHWAYS, AND TIMELINE 281
6.7.2 LICENSING AND REGISTRATION 281
6.7.3 POST-MARKETING SURVEILLANCE 281
7 PIPELINE ANALYSIS OF THE NORTH AMERICA FAT REDUCTION MARKET 282
8 MARKET ACCESS 289
8.1 MANUFACTURER AND STRATEGIC DEALS 289
8.2 CURRENT TREATMENT PRACTICES 289
8.3 IMPACT OF UPCOMING THERAPY 290
9 MARKET OVERVIEW 291
9.1 DRIVERS 293
9.1.1 INCREASING DEMAND FOR MINIMALLY INVASIVE AND NON-INVASIVE PROCEDURES 293
9.1.2 GROWING AESTHETIC CONSCIOUSNESS AND BEAUTY STANDARDS 294
9.1.3 GROWING TECHNOLOGICAL ADVANCEMENTS 295
9.1.4 DECREASED DISPARITY BETWEEN MEN AND WOMEN FOR AESTHETIC PROCEDURES 296
9.2 RESTRAINTS 297
9.2.1 HIGH COST OF PROCEDURES 297
9.2.2 INCREASED RISKS ASSOCIATED WITH THE PROCEDURES 298
9.2.3 PRODUCT RECALL 298
9.3 OPPORTUNITIES 299
9.3.1 CUSTOMIZED TREATMENT PLANS AND INTEGRATION WITH OTHER AESTHETIC PROCEDURES 299
9.3.2 BELIEF AND TREND OF FAT REDUCTION IN YOUNG ADULTS 300
9.3.3 FOCUS ON INCLUSIVITY AND DIVERSITY AND EXPANSION OF PRODUCT LINES 302
9.4 CHALLENGES 304
9.4.1 LONG-TERM EFFICACY AND SUSTAINABILITY 304
9.4.2 LONGER RECOVERY TIME OF THE PROCEDURE 304
10 NORTH AMERICA FAT REDUCTION MARKET, BY TYPE 306
10.1 OVERVIEW 307
10.2 SURGICAL FAT REDUCTION 310
10.2.1 LIPOSUCTION 311
10.2.1.1 BY TYPE 312
10.2.1.1.1 ULTRASOUND-ASSISTED LIPOSUCTION 312
10.2.1.1.2 LASER-ASSISTED LIPOSUCTION 313
10.2.1.1.3 TUMESCENT LIPOSUCTION 313
10.2.1.1.4 SUPER-WET TECHNIQUE 313
10.2.1.2 BY APPLICATION 313
10.2.1.2.1 ABDOMINAL FAT 314
10.2.1.2.2 THIGHS FAT 314
10.2.1.2.3 BUTTOCK FAT 314
10.2.1.2.4 UPPER-ARM FAT 314
10.2.1.2.5 FACIAL FAT-DEPOSITS 314
10.2.1.2.5.1 SUBMENTAL AREAS 315
10.2.1.2.5.2 MALAR 315
10.2.1.2.5.3 MANDIBULAR 315
10.2.1.2.6 KNEE FAT 315
10.2.2 SURGICAL REJUVENATION 315
10.2.2.1 FACE LIFT 316
10.2.2.2 NECK LIFT 316
10.2.3 CHIN IMPLANT 316
10.2.3.1 SILICONE CHIN IMPLANTS 317
10.2.3.2 OTHERS 317
10.2.4 PORUS IMPLANTS 317
10.2.4.1 TEFLON 318
10.2.4.2 GORE-TEX 318
10.2.4.3 MEDPORE IMPLANTS 318
10.3 NON-INVASIVE FAT REDUCTION 318
10.3.1 CRYOLIPOLYSIS 321
10.3.1.1 COOL SCULPTING 321
10.3.1.2 COOL SCULPTING ELITE 321
10.3.1.3 COOL TONE 322
10.3.1.4 OTHERS 322
10.3.1.4.1 ABDOMINAL FAT 322
10.3.1.4.2 THIGHS FAT 322
10.3.1.4.3 BUTTOCK FAT 323
10.3.1.4.4 UPPER-ARM FAT 323
10.3.1.4.5 FACIAL FAT-DEPOSITS 323
10.3.1.4.6 KNEE FAT 323
10.3.2 ULTRASOUND 323
10.3.2.1 INTERNAL ULTRASONIC LIPOSUCTION 324
10.3.2.2 EXTERNAL ULTRASONIC LIPOSUCTION 324
10.3.2.2.1 ABDOMINAL FAT 325
10.3.2.2.2 THIGHS FAT 325
10.3.2.2.3 BUTTOCK FAT 325
10.3.2.2.4 UPPER-ARM FAT 325
10.3.2.2.5 FACIAL FAT-DEPOSITS 325
10.3.2.2.6 KNEE FAT 325
10.3.3 RADIOFREQUENCY 326
10.3.3.1 ABDOMINAL FAT 326
10.3.3.2 THIGHS FAT 326
10.3.3.3 BUTTOCK FAT 326
10.3.3.4 UPPER-ARM FAT 326
10.3.3.5 FACIAL FAT-DEPOSITS 327
10.3.3.6 KNEE FAT 327
10.3.4 LOW LEVEL LASER THERAPY 327
10.3.4.1 ABDOMINAL FAT 327
10.3.4.2 THIGHS FAT 327
10.3.4.3 BUTTOCK FAT 328
10.3.4.4 UPPER-ARM FAT 328
10.3.4.5 FACIAL FAT-DEPOSITS 328
10.3.4.6 KNEE FAT 328
10.3.5 OTHERS 328
10.4 MINIMALLY INVASIVE 328
10.4.1 INJECTION LIPOLYSIS 330
10.4.1.1 DEOXYCHOLIC ACID INJECTIONS 330
10.4.1.1.1 KYBELLA/BELKYRA 331
10.4.1.1.1.1 FACIAL FAT-DEPOSITS 332
10.4.1.1.1.2 UPPER-ARM FAT 332
10.4.1.1.1.3 ABDOMINAL FAT 332
10.4.1.1.1.4 THIGHS FAT 332
10.4.1.1.1.5 KNEE FAT 332
10.4.1.1.1.6 BUTTOCK FAT 332
10.4.1.1.2 AQUALYX 333
10.4.1.1.2.1 FACIAL FAT-DEPOSITS 333
10.4.1.1.2.2 UPPER-ARM FAT 333
10.4.1.1.2.3 ABDOMINAL FAT 333
10.4.1.1.2.4 THIGHS FAT 334
10.4.1.1.2.5 KNEE FAT 334
10.4.1.1.2.6 BUTTOCK FAT 334
10.4.1.2 PHOSPHATIDYLCHOLINE 334
10.4.1.2.1 FACIAL FAT-DEPOSITS 335
10.4.1.2.2 UPPER-ARM FAT 335
10.4.1.2.3 ABDOMINAL FAT 335
10.4.1.2.4 THIGHS FAT 335
10.4.1.2.5 KNEE FAT 335
10.4.1.2.6 BUTTOCK FAT 335
10.4.1.3 OTHERS 335
10.4.2 OTHERS 335
11 NORTH AMERICA FAT REDUCTION MARKET, BY APPLICATION 336
11.1 OVERVIEW 337
11.2 ABDOMINAL FAT 340
11.3 THIGHS FAT 341
11.4 BUTTOCK FAT 342
11.5 UPPER-ARM FAT 343
11.6 FACIAL FAT-DEPOSITS 344
11.6.1 SUBMENTAL AREAS 345
11.6.2 MANDIBULAR 345
11.6.3 MALAR 345
11.7 KNEE FAT 345
12 NORTH AMERICA FAT REDUCTION MARKET, BY GENDER 347
12.1 OVERVIEW 348
12.2 FEMALE 351
12.3 MALE 352
13 NORTH AMERICA FAT REDUCTION MARKET, BY AGE GROUP 353
13.1 OVERVIEW 354
13.2 ADULT 357
13.3 GERIATRIC 358
13.4 CHILD 359
14 NORTH AMERICA FAT REDUCTION MARKET, BY END USER 361
14.1 OVERVIEW 362
14.2 HOSPITALS 365
14.2.1 BY TYPE 366
14.2.1.1 PRIVATE 366
14.2.1.2 PUBLIC 366
14.2.2 BY CATEGORY 366
14.2.2.1 TIER 1 367
14.2.2.2 TIER 2 367
14.2.2.3 TIER 3 367
14.3 MULTISPECIALTY CLINICS 367
14.4 DERMATOLOGY CENTERS 368
14.5 MEDICAL SPAS AND BEAUTY CENTERS 369
14.6 OTHERS 370

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.